Search

Your search keyword '"Dong ZhiLi"' showing total 565 results
Start Over Author "Dong ZhiLi"
565 results on '"Dong ZhiLi"'

5. Subfield Attacks on HSVP in Ideal Lattices

Author

Dong, Zhili, Tian, Shixin, Wang, Kunpeng, Lv, Chang, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, and Deng, Yi, editor

Published
2023
Full Text
View/download PDF

16. Pharmacokinetics and pharmacodynamics of the factor XIa‐inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies.

Author

Dong, Zhili, Hashizume, Kensei, Friedrichs, Frauke, Liu, Pei, Tanaka, Toshiaki, and Liao, Yuqin

Subjects
*PARTIAL thromboplastin time, *CHINESE people, *ANTIBODY titer, *VOLUNTEERS, *IMMUNE response
Abstract

The pharmacokinetics, pharmacodynamics, immunogenicity, and safety of osocimab single doses in healthy Chinese and Japanese volunteers over 149 days were evaluated. Two phase 1 single‐blinded, placebo‐controlled studies with 27 Japanese and 50 Chinese participants were conducted. Osocimab was investigated with IV doses of 0.3, 1.25, and 2.5 mg/kg (Chinese study) and 0.3, 1.25, and 5.0 mg/kg (Japanese study), as well as SC doses of 3.0 and 6.0 mg/kg (Chinese study) and 6.0 mg/kg (Japanese study). The maximum plasma concentration was reached 1–3 h and 4–6 days after IV and SC administration, respectively. Osocimab exhibited a deviation from dose‐proportional pharmacokinetics for AUC but not Cmax; higher doses had higher apparent clearance and disproportionately lower total exposure. A slightly lower exposure was observed in Japanese compared with Chinese volunteers after IV administration; conversely, relatively higher exposure in Japanese volunteers with SC dosing was identified. Osocimab was associated with a dose‐dependent increase in activated partial thromboplastin time (aPTT). Maximal aPTT prolongations were observed 1–4 h and 2–6 days after IV and SC administration, respectively. Anti‐drug antibodies of low titer were detected in 1/9 (11.1%) Japanese volunteers administered placebo and 26/40 (65.0%) Chinese volunteers administered osocimab. Adverse events were reported in 8/18 (44.4%) Japanese and 28/40 (70.0%) Chinese volunteers who received osocimab, as well as in 1/9 (11.1%) Japanese and 6/10 (60.0%) Chinese volunteers who received placebo. In conclusion, data did not suggest a clear dose‐proportionality for osocimab within the investigated dose range. The effect of osocimab on aPTT was expected per its mechanism of action. Osocimab was generally well tolerated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. List of contributors

Author

Abdellatif, Bey Temsamani, primary, Afendi, M., additional, Ahmad, Z., additional, Amin, N.A.M., additional, Angelova, Radostina A., additional, Ani, F.C., additional, Ariffin, A.K., additional, Aziz, N.A., additional, Cho, Nan, additional, Colangelo, Joseph, additional, Collins, Maurice N., additional, Coyle, Richard, additional, Dalton, Eric, additional, Daud, R., additional, Dong, Zhili, additional, Ferrier, Emmanuel, additional, Gharaibeh, Mohammad A., additional, Hua, Younan, additional, Jacobo, Víctor Hugo, additional, Li, Xiaoming, additional, Liu, Binghai, additional, Majid, M.S. Abdul, additional, Makhlouf, Abdel Salam Hamdy, additional, Mo, Zhiqiang, additional, Mohamad, A., additional, Ong, Kenny, additional, Ooi, E.P., additional, Ortiz, Armando, additional, Punch, Jeff, additional, Ren, Guang, additional, Rios-Soberanis, Carlos Rolando, additional, Saad, A.A., additional, Samsudin, Z., additional, Schouwenaars, Rafael, additional, Tran, Manh Tien, additional, Vu, Xuan Hong, additional, Wheeler, Jason, additional, Wolfgong, W. John, additional, Zhao, Yuzhe, additional, and Zulfiqar, S., additional

Published
2020
Full Text
View/download PDF

45. Laser Applications

Author

Kong, Ling Bing, Huang, Yizhong, Que, Wenxiu, Zhang, Tianshu, Li, Sean, Zhang, Jian, Dong, Zhili, Tang, Dingyuan, Bergmann, Carlos P., Series editor, Kong, Ling Bing, Huang, Y. Z., Que, W. X., Zhang, T. S., Li, S., Zhang, J., Dong, Z. L., and Tang, D. Y.

Published
2015
Full Text
View/download PDF

46. Sintering and Densification of Transparent Ceramics

Author

Kong, Ling Bing, Huang, Yizhong, Que, Wenxiu, Zhang, Tianshu, Li, Sean, Zhang, Jian, Dong, Zhili, Tang, Dingyuan, Bergmann, Carlos P., Series editor, Kong, Ling Bing, Huang, Y. Z., Que, W. X., Zhang, T. S., Li, S., Zhang, J., Dong, Z. L., and Tang, D. Y.

Published
2015
Full Text
View/download PDF

47. Grain Growth and Microstructure Development

Author

Kong, Ling Bing, Huang, Yizhong, Que, Wenxiu, Zhang, Tianshu, Li, Sean, Zhang, Jian, Dong, Zhili, Tang, Dingyuan, Bergmann, Carlos P., Series editor, Kong, Ling Bing, Huang, Y. Z., Que, W. X., Zhang, T. S., Li, S., Zhang, J., Dong, Z. L., and Tang, D. Y.

Published
2015
Full Text
View/download PDF

50. Powder Characterization and Compaction

Author

Kong, Ling Bing, Huang, Yizhong, Que, Wenxiu, Zhang, Tianshu, Li, Sean, Zhang, Jian, Dong, Zhili, Tang, Dingyuan, Bergmann, Carlos P., Series editor, Kong, Ling Bing, Huang, Y. Z., Que, W. X., Zhang, T. S., Li, S., Zhang, J., Dong, Z. L., and Tang, D. Y.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results